Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), End User (Biotechnology & Pharmaceutical Companies, CROs) - Global Forecast 2022

ゲノム編集/ゲノム工学の世界市場予測(~2022年):技術(CRISPR、TALEN、ZFN)、用途、エンドユーザー

◆タイトル:Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), End User (Biotechnology & Pharmaceutical Companies, CROs) - Global Forecast 2022
◆商品コード:BT-3380
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年11月20日
◆ページ数:166
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオ技術
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、ゲノム編集/ゲノム工学の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、技術別分析、用途別分析、需要先別分析、地域別分析、ゲノム編集/ゲノム工学の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“The genome editing/genome engineering market is projected to grow at a CAGR of 14.5%.”
The global genome editing market is expected to grow at a CAGR of 14.5% to reach to USD 6.28 billion by 2022. The key factors propelling the growth of this market are rising government funding and growth in the number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics.

“The CRISPR segment is expected to grow at the highest rate during the forecast period.”
By technology, the market is segmented into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine Base Editor (ADE), and Jump-In). The CRISPR segment is estimated to grow at the highest CAGR during the forecast period. The ease of use associated with the CRISPR technology is a significant advantage over ZFN and TALEN, especially in generating a large set of vectors to target numerous sites or even genome-wide libraries. Another potential advantage of CRISPR is its ability to multiplex, that is, to use multiple guide RNAs in parallel to target multiple sites simultaneously in the same cell. This makes it easier to mutate multiple genes at once or engineer precise deletions in a genomic region.

“The pharmaceutical and biotechnology companies segment is expected to be the fastest growing end-user segment.”
On the basis of end user, the market is classified into pharmaceutical and biotechnology companies, academic & government research institutes, and contract research organizations. The pharmaceutical and biotechnology companies segment is estimated to grow at the fastest rate during the forecast period. The increasing prevalence of infectious diseases and cancer are driving research activities worldwide; this is expected to drive the demand for genome editing in biotechnology & pharmaceutical companies.

“North America to dominate the genome editing/genome engineering market and is projected to grow at the highest CAGR during the forecast period.”
The North American region is expected to hold the largest share of the global market in 2017. This regional segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate of this region can be attributed to factors such as the development of gene therapy in the US, increasing use of genetically modified crops, rising prevalence of infectious diseases and cancer, and rising availability of research grants and funding.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1: 56%, Tier 2: 35%, and Tier 3: 9%
• By Designation – C-level: 27%, Director Level: 15%, Others: 58%
• By Region – North America: 37%, Europe: 23%, Asia Pacific: 25%, RoW: 15%

Thermo Fisher Scientific (US), Merck KGaA (Germany), and Horizon Discovery Group (UK) are some of the major players operating in the market.
Research Coverage:
The report analyzes the market and aims at estimating the market size and the future growth potential of this market based on various segments such as technology, application, end user, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned strategies.
This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global genome editing/genome engineering market
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global genome editing/genome engineering market
• Market Development: Comprehensive information about the lucrative emerging markets by technology, application, end user, and region
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global genome editing/genome engineering market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players in the global market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH DATA 20
2.1.1 SECONDARY DATA 22
2.1.1.1 Secondary sources 22
2.1.2 PRIMARY RESEARCH 23
2.1.2.1 Breakdown of primaries 23
2.1.2.2 Key data from primary sources 24
2.2 MARKET SIZE ESTIMATION 24
2.3 MARKET DATA VALIDATION AND TRIANGULATION 26
2.4 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 32
4.1 GENOME EDITING: MARKET OVERVIEW 32
4.2 EUROPE: GENOME EDITING MARKET, BY APPLICATION 33
4.3 GENOME EDITING MARKET, BY END USER 34
4.4 GENOME EDITING MARKET, BY COUNTRY/REGION 34
5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Rising government funding and growth in the number of
genomics projects 36
5.2.1.2 Growing application areas of genomics 38
5.2.1.3 High prevalence of infectious diseases and cancer 38
5.2.1.4 Technological advancements 39
5.2.1.5 Increasing production of genetically modified crops 39
5.2.2 RESTRAINTS 40
5.2.2.1 Dearth of trained professionals 40
5.2.2.2 Adverse public perception of genetic research 40
5.2.3 OPPORTUNITIES 40
5.2.3.1 Use of genome editing in specialized/personalized medicine 40
5.2.3.2 Emerging markets 41
5.2.4 CHALLENGES 42
5.2.4.1 High cost of genomics equipment 42
5.2.4.2 Off-target effect of CRISPR 42
5.2.4.3 Secure storage of large volumes of sequenced data 42
6 GENOME EDITING MARKET, BY TECHNOLOGY 43
6.1 INTRODUCTION 44
6.2 CRISPR 45
6.3 TALEN 46
6.4 ZFN 47
6.5 ANTISENSE 48
6.6 OTHER TECHNOLOGIES 49
7 GENOME EDITING MARKET, BY APPLICATION 51
7.1 INTRODUCTION 52
7.2 CELL LINE ENGINEERING 53
7.3 GENETIC ENGINEERING 54
7.3.1 ANIMAL GENETIC ENGINEERING 56
7.3.2 PLANT GENETIC ENGINEERING 57
7.4 OTHER APPLICATIONS 58
8 GENOME EDITING MARKET, BY END USER 60
8.1 INTRODUCTION 61
8.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 62
8.3 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 63
8.4 CONTRACT RESEARCH ORGANIZATIONS 64
9 GENOME EDITING MARKET, BY REGION 65
9.1 INTRODUCTION 66
9.2 NORTH AMERICA 68
9.2.1 US 72
9.2.1.1 Research grants and funding by government institutes 72
9.2.1.2 Increasing use of GM crops 73
9.2.1.3 Prevalence of Alzheimer’s disease and other dementias in the US 73

9.2.1.4 Genome editing conferences in the US 74
9.2.1.5 Increasing prevalence of cancer 74
9.2.1.6 Strategic developments in the US market 74
9.2.2 CANADA 76
9.2.2.1 Availability of research funding in Canada 76
9.2.2.2 Rising incidence of cancer 77
9.2.2.3 GAPP to intensify genomic R&D 78
9.3 EUROPE 80
9.3.1 GERMANY 84
9.3.1.1 Presence of a large number of academic institutes 84
9.3.1.2 Availability of funding for life science research 85
9.3.1.3 Conferences/Meetings/Symposiums/Workshops in Germany 85
9.3.2 UK 87
9.3.2.1 Increasing funds and grants by government bodies 87
9.3.2.2 100,000 Genomes Project in the UK 88
9.3.3 FRANCE 90
9.3.3.1 Increasing government investments in genomics 90
9.3.3.2 Introduction of noninvasive prenatal testing in France 91
9.3.4 ROE 92
9.3.4.1 Spain’s focus on research 92
9.3.4.2 Growth in the Italian biotech and pharma sectors 93
9.3.4.3 Growing research investments in Sweden & Denmark 93
9.4 ASIA PACIFIC 95
9.4.1 CHINA 98
9.4.1.1 Government initiatives to support healthcare research in China 98
9.4.1.2 Efforts of BGI to boost the genomics market in China 98
9.4.1.3 High intensity of R&D activities in China 99
9.4.2 JAPAN 100
9.4.2.1 Increasing government focus on cancer research 100
9.4.2.2 Conferences and symposiums on genetic engineering in Japan 101
9.4.2.3 Focus on cancer research and treatment 101
9.4.3 INDIA 103
9.4.3.1 Emergence of local players in India backed by government funding 103
9.4.3.2 Increasing support for biotech start-ups 104
9.4.3.3 Growth of the pharmaceutical industry in India 104
9.4.4 ROAPAC 106
9.4.4.1 Alliances and partnerships in the Australian market 106
9.4.4.2 Genome Asia 100K initiative 107
9.4.4.3 Crop research initiatives in Asia 107

9.5 ROW 109
9.5.1 LATIN AMERICA 111
9.5.1.1 Alliances, availability of government funding in Brazil 111
9.5.1.2 Conferences & workshops in Brazil (2016-2017) 112
9.5.2 MIDDLE EAST AND AFRICA 113
9.5.2.1 Genetic testing and genomic analysis in the Middle East 113
9.5.2.2 Rising prevalence of HIV and cancer in Africa 114
10 COMPETITIVE LANDSCAPE 117
10.1 KEY DEVELOPMENTS BY LEADING PLAYERS IN THE GENOME EDITING MARKET
(2014-2017) 117
10.2 MARKET SHARE ANALYSIS 118
10.2.1 THERMO FISHER SCIENTIFIC 118
10.2.2 MERCK 119
10.2.3 HORIZON DISCOVERY GROUP 119
10.3 COMPETITIVE SCENARIO 120
10.3.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 121
10.3.2 PRODUCT & SERVICE LAUNCHES, BY COMPANY 122
10.3.3 ACQUISITIONS 123
10.3.4 EXPANSIONS 124
11 COMPANY PROFILES 125
(BUSINESS OVERVIEW, PRODUCTS OFFERED, STRENGTH OF PRODUCT PORTFOLIO, BUSINESS STRATEGY EXCELLENCE, RECENT DEVELOPMENTS.)*
11.1 THERMO FISHER SCIENTIFIC 125
11.2 MERCK 129
11.3 HORIZON DISCOVERY GROUP 132
11.4 GENSCRIPT 136
11.5 SANGAMO BIOSCIENCES 139
11.6 INTEGRATED DNA TECHNOLOGIES 141
11.7 LONZA 143
11.8 NEW ENGLAND BIOLABS 146
11.9 ORIGENE TECHNOLOGIES 148
11.10 TRANSPOSAGEN BIOPHARMACEUTICALS 150
11.11 EDITAS MEDICINE 152
11.12 CRISPR THERAPEUTICS 154
*Details on Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key relationships might not be captured in case of unlisted companies.

12 APPENDIX 156
12.1 DISCUSSION GUIDE 156
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 160
12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 162
12.4 AVAILABLE CUSTOMIZATIONS 162
12.5 RELATED REPORTS 163
12.6 AUTHOR DETAILS 164

LIST OF TABLES

TABLE 1 GLOBAL GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 44
TABLE 2 CRISPR-BASED GENOME EDITING MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 45
TABLE 3 TALEN-BASED GENOME EDITING MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 46
TABLE 4 ZFN-BASED GENOME EDITING MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 47
TABLE 5 ANTISENSE-BASED GENOME EDITING MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 48
TABLE 6 GENOME EDITING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 50
TABLE 7 GLOBAL GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 52
TABLE 8 GENOME EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY,
2015–2022 (USD MILLION) 54
TABLE 9 GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 55
TABLE 10 GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY COUNTRY,
2015–2022 (USD MILLION) 56
TABLE 11 GENOME EDITING MARKET FOR ANIMAL GENETIC ENGINEERING, BY COUNTRY, 2015–2022 (USD MILLION) 57
TABLE 12 GENOME EDITING MARKET FOR PLANT GENETIC ENGINEERING, BY COUNTRY, 2015–2022 (USD MILLION) 58
TABLE 13 GENOME EDITING MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2015–2022 (USD MILLION) 59
TABLE 14 GLOBAL GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 61
TABLE 15 GENOME EDITING MARKET FOR BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2015–2022 (USD MILLION) 62
TABLE 16 GENOME EDITING MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2015–2022 (USD MILLION) 63
TABLE 17 GENOME EDITING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2015–2022 (USD MILLION) 64
TABLE 18 GENOME EDITING MARKET, BY REGION, 2015–2022 (USD MILLION) 67
TABLE 19 GENOME EDITING MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 67
TABLE 20 NORTH AMERICA: GENOME EDITING MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 70
TABLE 21 NORTH AMERICA: GENOME EDITING MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 70
TABLE 22 NORTH AMERICA: GENOME EDITING MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 71
TABLE 23 NORTH AMERICA: GENOME EDITING MARKET FOR GENETIC ENGINEERING,
BY TYPE, 2015–2022 (USD MILLION) 71
TABLE 24 NORTH AMERICA: GENOME EDITING MARKET, BY END USER,
2015–2022 (USD MILLION) 71
TABLE 25 US: GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 75
TABLE 26 US: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 75
TABLE 27 US: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 76
TABLE 28 US: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 76
TABLE 29 INDICATIVE LIST OF PROJECTS FUNDED BY GAPP IN 2014 78
TABLE 30 CANADA: GENOME EDITING MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 78
TABLE 31 CANADA: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 79
TABLE 32 CANADA: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE, 2015–2022 (USD MILLION) 79
TABLE 33 CANADA: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 79
TABLE 34 CONFERENCE, MEETING, COURSE AND WORKSHOP IN EUROPE (2014-2018) 82
TABLE 35 EUROPE: GENOME EDITING MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 82
TABLE 36 EUROPE: GENOME EDITING MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 83
TABLE 37 EUROPE: GENOME EDITING MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 83
TABLE 38 EUROPE: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE, 2015–2022 (USD MILLION) 84
TABLE 39 EUROPE: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 84
TABLE 40 CONFERENCES, MEETINGS, SYMPOSIUMS, WORKSHOPS IN GERMANY
(2014-2018) 85
TABLE 41 GERMANY: GENOME EDITING MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 86
TABLE 42 GERMANY: GENOME EDITING MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 86
TABLE 43 GERMANY: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE, 2015–2022 (USD MILLION) 87
TABLE 44 GERMANY: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 87
TABLE 45 UK: GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 89
TABLE 46 UK: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 89
TABLE 47 UK: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 89
TABLE 48 UK: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 90
TABLE 49 FRANCE: GENOME EDITING MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 91
TABLE 50 FRANCE: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 91
TABLE 51 FRANCE: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 92
TABLE 52 FRANCE: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 92
TABLE 53 ROE: GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 93
TABLE 54 ROE: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 94
TABLE 55 ROE: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 94
TABLE 56 FRANCE: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 94
TABLE 57 ASIA PACIFIC: GENOME EDITING MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 96
TABLE 58 ASIA PACIFIC: GENOME EDITING MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 97
TABLE 59 ASIA PACIFIC: GENOME EDITING MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 97
TABLE 60 ASIA PACIFIC: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE, 2015–2022 (USD MILLION) 97
TABLE 61 ASIA PACIFIC: GENOME EDITING MARKET, BY END USER,
2015–2022 (USD MILLION) 98
TABLE 62 CHINA: GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 99
TABLE 63 CHINA: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 99
TABLE 64 CHINA: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 100
TABLE 65 CHINA: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 100
TABLE 66 CONFERENCES, SYMPOSIA, & WORKSHOPS IN JAPAN, 2016-2018 101
TABLE 67 JAPAN: GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 102
TABLE 68 JAPAN: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 102
TABLE 69 JAPAN: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 102
TABLE 70 JAPAN: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 103
TABLE 71 INDIA: GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 105
TABLE 72 INDIA: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 105
TABLE 73 INDIA: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 105
TABLE 74 EUROPE: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 106
TABLE 75 ROAPAC: GENOME EDITING MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 107
TABLE 76 ROAPAC: GENOME EDITING MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 107
TABLE 77 ROAPAC: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 108
TABLE 78 ROAPAC: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 108
TABLE 79 ROW: GENOME EDITING MARKET, BY REGION, 2015–2022 (USD MILLION) 110
TABLE 80 ROW: GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 110
TABLE 81 ROW: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 110
TABLE 82 ROW: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 111
TABLE 83 ROW: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 111
TABLE 84 LATAM: GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 112
TABLE 85 LATAM: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 112
TABLE 86 LATAM: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 113
TABLE 87 LATAM: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 113
TABLE 88 HIV INFECTIONS AND AIDS-RELATED DEATHS IN THE MIDDLE EAST
AND AFRICA, 2014 115
TABLE 89 MEA: GENOME EDITING MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 115
TABLE 90 MEA: GENOME EDITING MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 115
TABLE 91 MEA: GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2015–2022 (USD MILLION) 116
TABLE 92 MEA: GENOME EDITING MARKET, BY END USER, 2015–2022 (USD MILLION) 116
TABLE 93 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, BY COMPANY
(2015–2017) 121
TABLE 94 PRODUCT & SERVICE LAUNCHES, BY COMPANY (2015–2017) 122
TABLE 95 ACQUISITIONS, BY COMPANY (2015–2017) 123
TABLE 96 EXPANSIONS, BY COMPANY (2015–2017) 124


LIST OF FIGURES

FIGURE 1 GLOBAL GENOME EDITING MARKET SEGMENTATION 18
FIGURE 2 GLOBAL GENOME EDITING MARKET: RESEARCH METHODOLOGY STEPS 20
FIGURE 3 RESEARCH DESIGN 21
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 23
FIGURE 5 BOTTOM-UP APPROACH 25
FIGURE 6 TOP-DOWN APPROACH 25
FIGURE 7 DATA TRIANGULATION METHODOLOGY 26
FIGURE 8 GLOBAL GENOME EDITING MARKET, BY TECHNOLOGY (2017–2022) 28
FIGURE 9 GLOBAL GENOME EDITING MARKET, BY APPLICATION,
2017 VS. 2022 (USD MILLION) 29
FIGURE 10 GLOBAL GENOME EDITING MARKET, BY END USER, 2017 VS. 2022 (USD MILLION) 30
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE GENOME EDITING MARKET 31
FIGURE 12 RISING GOVERNMENT FUNDING AND HIGH PREVALENCE OF INFECTIOUS DISEASES & CANCER—KEY GROWTH DRIVERS OF THE GENOME EDITING MARKET 32
FIGURE 13 CELL LINE ENGINEERING SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017 33
FIGURE 14 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES WILL CONTINUE TO DOMINATE THE GENOME EDITING MARKET IN 2022 34
FIGURE 15 NORTH AMERICA TO REGISTER THE HIGHEST CAGR IN THE FORECAST PERIOD 34
FIGURE 16 GENOME EDITING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35
FIGURE 17 GLOBAL GENOME EDITING MARKET, BY TECHNOLOGY,
2017 VS. 2022 (USD MILLION) 44
FIGURE 18 GLOBAL GENOME EDITING MARKET, BY APPLICATION,
2017 VS. 2022 (USD MILLION) 52
FIGURE 19 GENOME EDITING MARKET FOR GENETIC ENGINEERING, BY TYPE,
2017 VS. 2022 (USD MILLION) 55
FIGURE 20 GENOME EDITING MARKET, BY END USER, 2017 VS. 2022 (USD MILLION) 61
FIGURE 21 GENOME EDITING MARKET, BY REGION, 2017 VS. 2022 (USD MILLION) 66
FIGURE 22 NORTH AMERICA: GENOME EDITING MARKET SNAPSHOT 68
FIGURE 23 NORTH AMARICA: NUMBER OF NEW CANCER CASES, BY COUNTRY 69
FIGURE 24 PREVALENCE OF ALZHEIMER'S DISEASE IN THE US, BY AGE (2016) 73
FIGURE 25 EUROPE: GENOME EDITING MARKET SNAPSHOT 80
FIGURE 26 EUROPE: NUMBER OF NEW CANCER CASES, BY COUNTRY 81
FIGURE 27 ASIA PACIFIC: GENOME EDITING MARKET SNAPSHOT 95
FIGURE 28 APAC: NUMBER OF NEW CANCER CASES, BY TYPE 96
FIGURE 29 ROW: GENOME EDITING MARKET SNAPSHOT 109
FIGURE 30 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2016 118
FIGURE 31 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS—KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS 120
FIGURE 32 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, BY COMPANY
(2014–2017) 121
FIGURE 33 PRODUCT & SERVICE LAUNCHES, BY COMPANY (2014-2017) 122
FIGURE 34 ACQUISITIONS, BY COMPANY (2014–2017) 123
FIGURE 35 EXPANSIONS, BY COMPANY (2014–2017) 124
FIGURE 36 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 125
FIGURE 37 MERCK: COMPANY SNAPSHOT 129
FIGURE 38 HORIZON DISCOVERY: COMPANY SNAPSHOT 132
FIGURE 39 GENSCRIPT : COMPANY SNAPSHOT 136
FIGURE 40 SANGAMO BIOSCIENCES: COMPANY SNAPSHOT 139
FIGURE 41 LONZA: COMPANY SNAPSHOT 143
FIGURE 42 EDITAS MEDICINE: COMPANY SNAPSHOT 152


【レポートのキーワード】

ゲノム編集、ゲノム工学、ゲノム編集技術、CRISPR、TALEN、ZFN、ゲノム編集用途、細胞株、遺伝子

★調査レポート[ゲノム編集/ゲノム工学の世界市場予測(~2022年):技術(CRISPR、TALEN、ZFN)、用途、エンドユーザー] ( Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), End User (Biotechnology & Pharmaceutical Companies, CROs) - Global Forecast 2022 / BT-3380) 販売に関する免責事項
[ゲノム編集/ゲノム工学の世界市場予測(~2022年):技術(CRISPR、TALEN、ZFN)、用途、エンドユーザー] ( Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), End User (Biotechnology & Pharmaceutical Companies, CROs) - Global Forecast 2022 / BT-3380) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆